Chief Medical Officer Noah Berkowitz will depart July 3 to pursue other opportunities.
Already a Subscriber? Log in
Get Instant Access to This Article
Subscribe to Hartford Business Journal and get immediate access to all of our subscriber-only content and much more.
- Critical Hartford and Connecticut business news updated daily.
- Immediate access to all subscriber-only content on our website.
- Bi-weekly print or digital editions of our award-winning publication.
- Special bonus issues like the Hartford Book of Lists.
- Exclusive ticket prize draws for our in-person events.
Click here to purchase a paywall bypass link for this article.
New Haven-based biotech Arvinas said its chief medical officer will leave next month as the company continues a broader leadership and strategic transition following the recent federal approval of its first commercial drug.
According to a regulatory filing, Chief Medical Officer Noah Berkowitz will depart July 3 to pursue other opportunities. The company did not provide additional details about his departure, but said it has begun a search for his replacement.
Berkowitz joined Arvinas in March 2024 from Bristol-Myers Squibb.
The announcement comes less than two months after Arvinas received U.S. Food and Drug Administration approval for VEPPANU, its first marketed drug, for certain patients with advanced or metastatic breast cancer. Shortly after the approval, Arvinas and partner Pfizer signed a licensing agreement with California-based Rigel Pharmaceuticals that could generate up to $405 million in upfront, milestone and royalty payments tied to the drug.
Arvinas has undergone significant changes over the past year, including leadership turnover, workforce reductions and a strategic effort to focus resources on its research pipeline. CEO Randy Teel took over the company earlier this year.
Under a separation agreement, Berkowitz will receive nine months of salary continuation, up to nine months of health insurance benefits, and accelerated vesting of certain restricted stock units that otherwise would have vested by May 9, 2027, according to the filing.
Arvinas is headquartered in New Haven's Science Park and had approximately $615 million in cash, cash equivalents and marketable securities as of March 31.
